Retinal Diagnostic Center | Campbell, CA

Research site

(Unclaimed)

Location

3394 S Bascom Avenue, Campbell, California, United States of America

Site insights

Top conditions

Top treatments

Faricimab

APL-2

Lampalizumab

Ranibizumab

Zimura

Avacincaptad pegol

Pegcetacoplan

Triamcinolone Acetonide

Strontium90 Beta

Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 34 total trials

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling

Diabetic Macular Edema

Drug: Faricimab

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

Wet AMD

Genetic: RGX-314

Biological: Ranibizumab (LUCENTIS®)

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Biological: Aflibercept (EYLEA®)

Genetic: ABBV-RGX-314 Dose 2

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling

Diabetic Retinopathy (DR)

Genetic: RGX-314 Dose 1

Genetic: RGX-314 Dose 2